Highlights & Basics
- Diabetic ketoacidosis (DKA) is characterized by a biochemical triad of hyperglycemia, ketonemia, and acidemia, with rapid symptom onset.
- Common symptoms and signs include polyuria, polydipsia, polyphagia, weakness, weight loss, tachycardia, dry mucous membranes, poor skin turgor, hypotension, and, in severe cases, shock.
- Successful treatment includes correction of volume depletion, hyperglycemia, electrolyte imbalances, and comorbid precipitating events, with frequent monitoring.
- Complications of treatment include hypoglycemia, hypokalemia, hypoxemia, and rarely pulmonary edema.
- Cerebral edema, a rare but potentially rapidly fatal complication, occurs mainly in children. It may be prevented by avoiding overly rapid fluid and electrolyte replacement.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Triad of DKA
Pathogenesis of DKA and HHS; triggers include stress, infection, and insufficient insulin. FFA: free fatty acid; HHS: hyperosmolar hyperglycemic state
Management of adult DKA. Abbreviations: blood glucose (BG); diabetic ketoacidosis (DKA); hour (h); intravenous (IV); subcutaneous (SC)
Algorithm for the management of potassium and bicarbonate
Citations
Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2009 Jul;32(7):1335-43.[Abstract][Full Text]
American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S1-321.[Full Text]
Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016 Apr;12(4):222-32.[Abstract]
1. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2009 Jul;32(7):1335-43.[Abstract][Full Text]
2. Balasubramanyam A, Nalini R, Hampe CS, et al. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008 May;29(3):292-302.[Abstract][Full Text]
3. American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S1-321.[Full Text]
4. Umpierrez GE, Woo W, Hagopian WA, et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care. 1999 Sep;22(9):1517-23.[Abstract]
5. Mauvais-Jarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004 Mar;53(3):645-53.[Abstract][Full Text]
6. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006 Mar 7;144(5):350-7.[Abstract]
7. Kitabchi AE, Umpierrez GE, Fisher JN, et al. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab. 2008 May;93(5):1541-52.[Abstract]
8. Benoit SR, Zhang Y, Geiss LS, et al. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality - United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-65.[Abstract][Full Text]
9. Centers for Disease Control and Prevention. National diabetes statistics report, 2017. February 2018 [internet publication].[Full Text]
10. Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016 Apr;12(4):222-32.[Abstract]
11. Vuk A, Baretic M, Osvatic MM, et al. Treatment of diabetic ketoacidosis associated with antipsychotic medication: literature review. J Clin Psychopharmacol. 2017 Oct;37(5):584-9.[Abstract]
12. Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc. 1987 Aug;35(8):737-41.[Abstract]
13. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.[Abstract][Full Text]
14. Kum-Nji JS, Gosmanov AR, Steinberg H, et al. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. J Diabetes Complications. 2017 Mar;31(3):611-4[Abstract]
15. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019 Jun;42(6):1147-54.[Abstract][Full Text]
16. Razavi Nematollahi L, Kitabchi AE, Stentz FB, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009 Apr;58(4):443-8.[Abstract]
17. Stentz FB, Umpierrez GE, Cuervo R, et al. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004 Aug;53(8):2079-86.[Abstract][Full Text]
18. Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003 Nov;88(11):5090-8.[Abstract]
19. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53.[Abstract][Full Text]
20. Price HC, Ismail K, Joint British Diabetes Societies (JBDS) for Inpatient Care. Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS): guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings. Diabet Med. 2018 Aug;35(8):997-1004.[Abstract][Full Text]
21. Lindner LME, Rathmann W, Rosenbauer J. Inequalities in glycaemic control, hypoglycaemia and diabetic ketoacidosis according to socio-economic status and area-level deprivation in Type 1 diabetes mellitus: a systematic review. Diabet Med. 2018 Jan;35(1):12-32.[Abstract]
22. Hamblin PS, Topliss DJ, Chosich N, et al. Deaths associated with diabetic ketoacidosis and hyperosmolar coma. 1973-1988. Med J Aust. 1989 Oct 16;151(8):439, 441-2, 444.[Abstract]
23. Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000 Oct;95(10):2795-800.[Abstract]
24. Kopff B, Mucha S, Wolffenbuttel BH, et al. Diabetic ketoacidosis in a patient with acromegaly. Med Sci Monit. 2001 Jan-Feb;7(1):142-7.[Abstract]
25. Cooppan R, Kozak GP. Hyperthyroidism and diabetes mellitus. An analysis of 70 patients. Arch Intern Med. 1980 Mar;140(3):370-3.[Abstract]
26. Alavi IA, Sharma BK, Pillay VK. Steroid-induced diabetic ketoacidosis. Am J Med Sci. 1971 Jul;262(1):15-23.[Abstract]
27. Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, et al. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502.[Abstract]
28. Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005 Dec;19 Suppl 1:1-93.[Abstract]
29. Nyenwe EA, Loganathan RS, Blum S, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract. 2007 Jan-Feb;13(1):22-9.[Abstract]
30. US Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. December 2015 [internet publication].[Full Text]
31. Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med. 2016 Jun;239(2):155-8.[Abstract][Full Text]
32. Clotman K, Janssens K, Specenier P, et al. Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-54.[Abstract]
33. Kirwan JP, Aminian A, Kashyap SR, Bet al. Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care. 2016 Jun;39(6):941-8.[Abstract][Full Text]
34. Runyan JW Jr, Zwaag RV, Joyner MB, et al. The Memphis diabetes continuing care program. Diabetes Care. 1980 Mar-Apr;3(2):382-6.[Abstract]
35. Vanelli M, Chiari G, Ghizzoni L, et al. Effectiveness of a prevention program for diabetes ketoacidosis in children. An 8-year study in schools and private practices. Diabetes Care. 1999 Jan;22(1):7-9.[Abstract]
36. Weber C, Kocher S, Neeser K, et al. Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Curr Med Res Opin. 2009 May;25(5):1197-207.[Abstract]
37. Henry RR, Dandona P, Pettus J, et al. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab. 2017 Jun;19(6):814-21.[Abstract]
38. Goldenberg RM, Berard LD, Cheng AY, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016 Dec;38(12):2654-64.e1.[Abstract]
39. Kitabchi AE. Editorial. Hyperglycemic crises: improving prevention and management. Am Fam Physician. 2005 May 1;71(9):1659-60.[Abstract][Full Text]
40. Joseph F, Anderson L, Goenka N, et al. Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. J Gen Intern Med. 2009 Jan;24(1):129-31.[Abstract][Full Text]
41. Kemperman FA, Weber JA, Gorgels J, et al. The influence of ketoacids on plasma creatinine assays in diabetic ketoacidosis. J Intern Med. 2000 Dec;248(6):511-7.[Abstract][Full Text]
42. Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016 Winter;13(4):217-25.[Abstract]
43. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015-38.[Abstract]
44. Nyenwe EA, Razavi LN, Kitabchi AE, et al. Acidosis: the prime determinant of depressed sensorium in diabetic ketoacidosis. Diabetes Care. 2010 Aug;33(8):1837-9.[Abstract][Full Text]
45. Matz R. Hypothermia in diabetic acidosis. Hormones. 1972;3(1):36-41.[Abstract]
46. Fasanmade OA, Odeniyi IA, Ogbera AO. Diabetic ketoacidosis: diagnosis and management. Afr J Med Med Sci. 2008 Jun;37(2):99-105.[Abstract]
47. Andrade OV, Ihara FO, Troster EJ. Metabolic acidosis in childhood: why, when and how to treat. J Pediatr (Rio J). 2007 May;83(2 Suppl):S11-21.[Abstract]
48. Piva JP, Czepielewskii M, Garcia PC, et al. Current perspectives for treating children with diabetic ketoacidosis. J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S119-27. [Abstract]
49. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.[Abstract][Full Text]
50. Colquhoun MC, Handley AJ, Evans TR. ABC of resuscitation. 5th ed. London: BMJ Publishing Group; 2004.
51. Chrimes N, Higgs A, Hagberg CA, et al. Preventing unrecognised oesophageal intubation: a consensus guideline from the Project for Universal Management of Airways and international airway societies. Anaesthesia. 2022 Dec;77(12):1395-415. [Abstract][Full Text]
52. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-143.[Abstract][Full Text]
53. Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014 Jun 30;7:255-64.[Abstract][Full Text]
54. Hom J, Sinert R. Evidence-based emergency medicine/critically appraised topic. Is fluid therapy associated with cerebral edema in children with diabetic ketoacidosis? Ann Emerg Med. 2008 Jul;52(1):69-75.e1.[Abstract]
55. Levin DL. Cerebral edema in diabetic ketoacidosis. Pediatr Crit Care Med. 2008 May;9(3):320-9.[Abstract]
56. Joint British Diabetes Societies Inpatient Care Group. The management of diabetic ketoacidosis in adults. Jun 2021 [internet publication].[Full Text]
57. Hillman K. Fluid resuscitation in diabetic emergencies - a reappraisal. Intensive Care Med. 1987;13(1):4-8.[Abstract]
58. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med. 1977 Aug 4;297(5):238-41.[Abstract]
59. Umpierrez GE, Cuervo R, Karabell A, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004 Aug;27(8):1873-8.[Abstract][Full Text]
60. Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004 Sep 1;117(5):291-6.[Abstract]
61. Ludvigsson J, Samuelsson U. Continuous insulin infusion (CSII) or modern type of multiple daily injections (MDI) in diabetic children and adolescents: a critical review on a controversial issue. Pediatr Endocrinol Rev. 2007 Dec;5(2):666-78.[Abstract]
62. Mukhopadhyay A, Farrell T, Fraser RB, et al. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol. 2007 Nov;197(5):447-56.[Abstract]
63. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, et al. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011281.[Abstract][Full Text]
64. Chua HR, Schneider A, Bellomo R. Bicarbonate in diabetic ketoacidosis - a systematic review. Ann Intensive Care. 2011 Jul 6;1(1):23.[Abstract][Full Text]
65. Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med. 1986 Dec;105(6):836-40.[Abstract]
66. Kusminsky RE. Complications of central venous catheterization. J Am Coll Surg. 2007 Apr;204(4):681-96.[Abstract]
67. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003 Mar 20;348(12):1123-33.[Abstract][Full Text]
68. Smith RN, Nolan JP. Central venous catheters. BMJ. 2013 Nov 11;347:f6570.[Abstract][Full Text]
69. Reich DL. Monitoring in anesthesia and perioperative care. Cambridge: Cambridge University Press; 2011.
70. Abbott Northwestern Hospital Internal Medicine Residency. Internal jugular central venous line. 2022 [internet publication].[Full Text]
71. Bishop L, Dougherty L, Bodenham A, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007 Aug;29(4):261-78.[Abstract]
72. Practice guidelines for central venous access 2020: an updated report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2020 Jan;132(1):8-43.[Abstract][Full Text]
73. Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth. 2000 Aug;85(2):188-91.[Abstract]
74. Gibson F, Bodenham A. Misplaced central venous catheters: applied anatomy and practical management. Br J Anaesth. 2013 Mar;110(3):333-46.[Abstract][Full Text]
75. Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth. 2000 Aug;85(2):192-4.[Abstract]
76. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019 Jan 23;(1):CD007798.[Abstract][Full Text]
77. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab. 1983 Jul;57(1):177-80.[Abstract]
78. Adrogue HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med. 1982 Dec 23;307(26):1603-10.[Abstract]
79. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-28.[Abstract][Full Text]
80. Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018 Oct;19(suppl 27):155-77.[Abstract]
81. Duck SC, Wyatt DT. Factors associated with brain herniation in the treatment of diabetic ketoacidosis. J Pediatr. 1988 Jul;113(1 Pt 1):10-4.[Abstract]
82. Glaser N. New perspectives on the pathogenesis of cerebral edema complicating diabetic ketoacidosis in children. Pediatr Endocrinol Rev. 2006 Jun;3(4):379-86.[Abstract]
83. Kuppermann N, Ghetti S, Schunk JE,et al; PECARN DKA FLUID Study Group. Clinical trial of fluid infusion rates for pediatric diabeticketoacidosis. N Engl J Med. 2018 Jun 14;378(24):2275-87.[Abstract]
84. Carroll P, Matz R. Adult respiratory distress syndrome complicating severely uncontrolled diabetes mellitus: report of nine cases and a review of the literature. Diabetes Care. 1982 Nov-Dec;5(6):574-80[Abstract]
85. Buyukasik Y, Ileri NS, Haznedaroglu IC, et al. Enhanced subclinical coagulation activation during diabetic ketoacidosis. Diabetes Care. 1998 May;21(5):868-70.[Abstract]
86. Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: physiologic versus pharmacologic doses of insulin and their routes of administration. In: Brownlee M, ed. Handbook of diabetes mellitus. New York, NY: Garland ATPM Press; 1981:95-149.
87. Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis? Ann Emerg Med. 2009 Feb;53(2):259-63.[Abstract]
88. Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes: a national clinical guideline. November 2017 [internet publication].[Full Text]
Key Articles
Referenced Articles
Sign in to access our clinical decision support tools